Who are Erlotinib, Pemetrexed's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/erlotinib-pemetrexed.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Erlotinib, Pemetrexed — Competitive Intelligence Brief

Erlotinib, Pemetrexed (Erlotinib, Pemetrexed) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: EGFR tyrosine kinase inhibitor + antifolate antimetabolite. Area: Oncology.

marketed EGFR tyrosine kinase inhibitor + antifolate antimetabolite EGFR; thymidylate synthase and folate-dependent enzymes Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Erlotinib, Pemetrexed (Erlotinib, Pemetrexed) — Hunan Province Tumor Hospital. This combination uses erlotinib to inhibit EGFR signaling and pemetrexed to disrupt folate-dependent nucleotide synthesis, together targeting non-small cell lung cancer through dual pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Erlotinib, Pemetrexed TARGET	Erlotinib, Pemetrexed	Hunan Province Tumor Hospital	marketed	EGFR tyrosine kinase inhibitor + antifolate antimetabolite	EGFR; thymidylate synthase and folate-dependent enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (EGFR tyrosine kinase inhibitor + antifolate antimetabolite class)

Hunan Province Tumor Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Erlotinib, Pemetrexed — Competitive Intelligence Brief. https://druglandscape.com/ci/erlotinib-pemetrexed. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab